Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates

Christophe Le Terrier¹, Patrice Nordmann², Adam Delaval³, Laurent Poirel⁴; NARA Network

Collaborators, Affiliations

Collaborators

NARA Network:
R Lienhard⁵, L Vonallmen⁵, C Schilt⁵, A Scherler⁵, K Lucke⁶, M Jutzi⁶, M Reichmuth⁶, V Slutter⁷, P A Gras⁸, B Suter⁹, U Schibli⁹, C Fricker⁹, S Pranghofer¹⁰, K Graff¹⁰, S Graf¹⁰, G Greub¹¹, D Blanc¹¹, A Vitale¹², B Lemaire¹², M Fatoux¹², M Tritten¹², T Simonet¹², L Rumebe¹³, N Liassine¹³, G Jost¹³, M Rosselin¹³, N Wohlwend¹⁴, D Schultze¹⁴, K Burren¹⁵, A Westers¹⁵, M Imperiali¹⁶, L Pozzi¹⁶, D Balzari¹⁶, G Vaninetti¹⁶, C Cirillo¹⁶, V Gaia¹⁷, E Pianezzi¹⁷, G L Mueller¹⁷, A Jayol¹⁸, C Guyon¹⁸, D Hyden¹⁹, M Maitrejean¹⁹, V Deggi-Messmer²⁰, D Bandeira²⁰, C Fournier²⁰, H Assman²¹, C Nusbaumer²², L Bertaiola Monnerat²², J Schrenzel²³, G Renzi²³, A Cherkaoui²³, D Andrey²³, A Nguyen²³, S Emonet²⁴, M Eyer²⁴, R Maret²⁴, A V Belo²⁴, D Mabillard²⁴, M Moraz²⁴, K Herzog²⁵, V Gisler²⁶, E Hitz²⁶, M Oberle²⁶, H Fankhauser²⁶, N Dubey²⁷, R Capaul²⁸, C Guler²⁸, M Schoenenberger²⁹, U Karrer²⁹, F Imeri³⁰, H Hinrikson³⁰, F Piran³¹, A Ergani³¹, C Andreutti³², M Dessauges³², M Aerni³³, T Schmid³³, I Mitrovic³⁴, E Gruner³⁵, V Bruderer³⁵, D Dimitrijevic³⁶, Y Guillod³⁶, C Maffioli³⁶, J Maurer³⁶, M Michel Blanco³⁶, M Vogel³⁶, R Wampfler³⁶, P Staehli³⁷, B Schnell³⁷, C Zehnder³⁸, V Di Lorenzo³⁹, C Payen³⁹, D Boschung³⁹, L Comte³⁹, M Schacher⁴⁰, M Brandenberger⁴⁰, C Zowa⁴⁰, C O Marti⁴¹, S Trachsel⁴², M C Descombes⁴³, I Steffen⁴⁴, C Kurmann⁴⁵, B von Arb⁴⁵, M Wehrli⁴⁶, B Elmer⁴⁶, A Imhof⁴⁷, B Preiswerk⁴⁸, B Mathis⁴⁹, L Martinotti⁵⁰, L Basilico⁵⁰, G Togni⁵⁰, P Minkova⁵¹, M Kuegler⁵¹, V Povolo⁵¹, S Droz⁵², M Elzi⁵², C Casanova⁵², D Goldenberger⁵³, P Keller⁵³, C Lang⁵³, A Blaich⁵³, S Schmid⁵³, B Ivan⁵³, A Egli⁵⁴, S Mancini⁵⁴, O Dubuis⁵⁵, K Narr⁵⁵, S Schoch⁵⁵, S Ellenberger⁵⁵, C Castelberg⁵⁵, S Seiffert⁵⁶

Affiliations

¹ Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
² Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
³ Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland.
⁴ Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland. Electronic address: laurent.poirel@unifr.ch.
⁵ ADMED Microbiologie La Chaux-de-Fonds, Switzerland.
⁶ Analytica Med. Laboratorien AG Zurich, Switzerland.
⁷ ANAMED SA Lausanne, Switzerland.
⁸ BACTOLAB AG Lausanne, Aarau, Switzerland.
⁹ Bakteriologisches Institut Olten AG Olten, Switzerland.
¹⁰ Bioanalytica AG Luzern, Switzerland.
¹¹ CHUV Lausanne, Switzerland.
¹² Clinique de La Source Lausanne CLS Lausanne, Switzerland.
¹³ Dianalabs Genève, Switzerland.
¹⁴ Dr Luc Salamin SA Sierre, Switzerland; Dr. Risch Ostschweiz AG Buchs, Switzerland.
¹⁵ Dr. Risch Liebefeld Liebefeld, Switzerland.
¹⁶ Dr. Risch Ticino SA Pregassona, Switzerland.
¹⁷ EOC-BELLINZONA Bellinzona, Switzerland.
¹⁸ Etablissements Hospitaliers Nord Vaudois (eHnv) Yverdon-Les-Bains, Switzerland.
¹⁹ Groupement Hospitalier de l'Ouest Lémanique S.A. (GHOL) Nyon, Switzerland.
²⁰ HFR hôpital fribourgeois Fribourg, Switzerland.
²¹ Hirslanden klinik Aarau Aarau, Switzerland.
²² Hôpital du Jura Delémont et Porrentruy, Switzerland.
²³ HUG Hôpitaux Universitaires Genève Geneva, Switzerland.
²⁴ Institut Central des Hôpitaux (ICH) Sion, Switzerland.
²⁵ Institut für Labormedizin Spital Thurgau AG Munsterlingen, Switzerland.
²⁶ Kantonsspital Aarau AG Aarau, Switzerland.
²⁷ Kantonsspital Baselland Liestal, Switzerland.
²⁸ Kantonsspital Graubünden Chur, Switzerland.
²⁹ Kantonsspital Winterthur Winterthur, Switzerland.
³⁰ lg1 Laborgemeinschaft 1 Zurich, Switzerland.
³¹ Laboratoire MGD Genève, Switzerland.
³² Laboratoires médicaux LabPoint Avenches et Lugano, Switzerland.
³³ Labor Team W AG Goldach, Switzerland.
³⁴ Luzerner Kantonsspital Luzern, Switzerland.
³⁵ Medica Medizinische Laboratorien Zurich, Switzerland.
³⁶ MCL Niederwangen, Switzerland.
³⁷ Medics Labor AG Bern, Switzerland.
³⁸ Medisyn SA Bioggio, Switzerland.
³⁹ Medisyn SA Lausanne, Switzerland.
⁴⁰ Medisyn AG Luzern, Switzerland.
⁴¹ Promed Laboratoire Médical SA Marly, Switzerland.
⁴² Proxilab analyses médicales SA Yverdon-les-Bains, Switzerland.
⁴³ Proxilis SA Meyrin, Switzerland.
⁴⁴ Rothen Medizinische Laboratorien AG Basel, Switzerland.
⁴⁵ Schweizer Paraplegiker Zentrum - SPZ Nottwil, Switzerland.
⁴⁶ Spitäler Schaffhausen Schaffhausen, Switzerland.
⁴⁷ SRO AG - Labor Langenthal, Switzerland.
⁴⁸ Stadtspital Triemli Zürich Zurich, Switzerland.
⁴⁹ Unilabs Breganzona, Switzerland.
⁵⁰ Unilabs Coppet - Core Lab Ouest Coppet, Switzerland.
⁵¹ Unilabs Dübendorf - Core Lab Ost Dübendorf, Switzerland.
⁵² Universität Bern Klinische Mikrobiologie Bern, Switzerland.
⁵³ Universität Spital Basel Basel, Switzerland.
⁵⁴ Universität Spital Zürich Zürich, Switzerland.
⁵⁵ Viollier AG Allschwill, Switzerland.
⁵⁶ Zentrum für Labormedizin St-Gallen, Switzerland.

PMID: 39447746
DOI: 10.1016/j.cmi.2024.10.012

Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates

Christophe Le Terrier et al. Clin Microbiol Infect. 2025 Jan.

. 2025 Jan;31(1):122-124.

doi: 10.1016/j.cmi.2024.10.012. Epub 2024 Oct 22.

Authors

Christophe Le Terrier¹, Patrice Nordmann², Adam Delaval³, Laurent Poirel⁴; NARA Network

Collaborators

NARA Network:
R Lienhard⁵, L Vonallmen⁵, C Schilt⁵, A Scherler⁵, K Lucke⁶, M Jutzi⁶, M Reichmuth⁶, V Slutter⁷, P A Gras⁸, B Suter⁹, U Schibli⁹, C Fricker⁹, S Pranghofer¹⁰, K Graff¹⁰, S Graf¹⁰, G Greub¹¹, D Blanc¹¹, A Vitale¹², B Lemaire¹², M Fatoux¹², M Tritten¹², T Simonet¹², L Rumebe¹³, N Liassine¹³, G Jost¹³, M Rosselin¹³, N Wohlwend¹⁴, D Schultze¹⁴, K Burren¹⁵, A Westers¹⁵, M Imperiali¹⁶, L Pozzi¹⁶, D Balzari¹⁶, G Vaninetti¹⁶, C Cirillo¹⁶, V Gaia¹⁷, E Pianezzi¹⁷, G L Mueller¹⁷, A Jayol¹⁸, C Guyon¹⁸, D Hyden¹⁹, M Maitrejean¹⁹, V Deggi-Messmer²⁰, D Bandeira²⁰, C Fournier²⁰, H Assman²¹, C Nusbaumer²², L Bertaiola Monnerat²², J Schrenzel²³, G Renzi²³, A Cherkaoui²³, D Andrey²³, A Nguyen²³, S Emonet²⁴, M Eyer²⁴, R Maret²⁴, A V Belo²⁴, D Mabillard²⁴, M Moraz²⁴, K Herzog²⁵, V Gisler²⁶, E Hitz²⁶, M Oberle²⁶, H Fankhauser²⁶, N Dubey²⁷, R Capaul²⁸, C Guler²⁸, M Schoenenberger²⁹, U Karrer²⁹, F Imeri³⁰, H Hinrikson³⁰, F Piran³¹, A Ergani³¹, C Andreutti³², M Dessauges³², M Aerni³³, T Schmid³³, I Mitrovic³⁴, E Gruner³⁵, V Bruderer³⁵, D Dimitrijevic³⁶, Y Guillod³⁶, C Maffioli³⁶, J Maurer³⁶, M Michel Blanco³⁶, M Vogel³⁶, R Wampfler³⁶, P Staehli³⁷, B Schnell³⁷, C Zehnder³⁸, V Di Lorenzo³⁹, C Payen³⁹, D Boschung³⁹, L Comte³⁹, M Schacher⁴⁰, M Brandenberger⁴⁰, C Zowa⁴⁰, C O Marti⁴¹, S Trachsel⁴², M C Descombes⁴³, I Steffen⁴⁴, C Kurmann⁴⁵, B von Arb⁴⁵, M Wehrli⁴⁶, B Elmer⁴⁶, A Imhof⁴⁷, B Preiswerk⁴⁸, B Mathis⁴⁹, L Martinotti⁵⁰, L Basilico⁵⁰, G Togni⁵⁰, P Minkova⁵¹, M Kuegler⁵¹, V Povolo⁵¹, S Droz⁵², M Elzi⁵², C Casanova⁵², D Goldenberger⁵³, P Keller⁵³, C Lang⁵³, A Blaich⁵³, S Schmid⁵³, B Ivan⁵³, A Egli⁵⁴, S Mancini⁵⁴, O Dubuis⁵⁵, K Narr⁵⁵, S Schoch⁵⁵, S Ellenberger⁵⁵, C Castelberg⁵⁵, S Seiffert⁵⁶

Affiliations

¹ Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
² Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
³ Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland.
⁴ Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland. Electronic address: laurent.poirel@unifr.ch.
⁵ ADMED Microbiologie La Chaux-de-Fonds, Switzerland.
⁶ Analytica Med. Laboratorien AG Zurich, Switzerland.
⁷ ANAMED SA Lausanne, Switzerland.
⁸ BACTOLAB AG Lausanne, Aarau, Switzerland.
⁹ Bakteriologisches Institut Olten AG Olten, Switzerland.
¹⁰ Bioanalytica AG Luzern, Switzerland.
¹¹ CHUV Lausanne, Switzerland.
¹² Clinique de La Source Lausanne CLS Lausanne, Switzerland.
¹³ Dianalabs Genève, Switzerland.
¹⁴ Dr Luc Salamin SA Sierre, Switzerland; Dr. Risch Ostschweiz AG Buchs, Switzerland.
¹⁵ Dr. Risch Liebefeld Liebefeld, Switzerland.
¹⁶ Dr. Risch Ticino SA Pregassona, Switzerland.
¹⁷ EOC-BELLINZONA Bellinzona, Switzerland.
¹⁸ Etablissements Hospitaliers Nord Vaudois (eHnv) Yverdon-Les-Bains, Switzerland.
¹⁹ Groupement Hospitalier de l'Ouest Lémanique S.A. (GHOL) Nyon, Switzerland.
²⁰ HFR hôpital fribourgeois Fribourg, Switzerland.
²¹ Hirslanden klinik Aarau Aarau, Switzerland.
²² Hôpital du Jura Delémont et Porrentruy, Switzerland.
²³ HUG Hôpitaux Universitaires Genève Geneva, Switzerland.
²⁴ Institut Central des Hôpitaux (ICH) Sion, Switzerland.
²⁵ Institut für Labormedizin Spital Thurgau AG Munsterlingen, Switzerland.
²⁶ Kantonsspital Aarau AG Aarau, Switzerland.
²⁷ Kantonsspital Baselland Liestal, Switzerland.
²⁸ Kantonsspital Graubünden Chur, Switzerland.
²⁹ Kantonsspital Winterthur Winterthur, Switzerland.
³⁰ lg1 Laborgemeinschaft 1 Zurich, Switzerland.
³¹ Laboratoire MGD Genève, Switzerland.
³² Laboratoires médicaux LabPoint Avenches et Lugano, Switzerland.
³³ Labor Team W AG Goldach, Switzerland.
³⁴ Luzerner Kantonsspital Luzern, Switzerland.
³⁵ Medica Medizinische Laboratorien Zurich, Switzerland.
³⁶ MCL Niederwangen, Switzerland.
³⁷ Medics Labor AG Bern, Switzerland.
³⁸ Medisyn SA Bioggio, Switzerland.
³⁹ Medisyn SA Lausanne, Switzerland.
⁴⁰ Medisyn AG Luzern, Switzerland.
⁴¹ Promed Laboratoire Médical SA Marly, Switzerland.
⁴² Proxilab analyses médicales SA Yverdon-les-Bains, Switzerland.
⁴³ Proxilis SA Meyrin, Switzerland.
⁴⁴ Rothen Medizinische Laboratorien AG Basel, Switzerland.
⁴⁵ Schweizer Paraplegiker Zentrum - SPZ Nottwil, Switzerland.
⁴⁶ Spitäler Schaffhausen Schaffhausen, Switzerland.
⁴⁷ SRO AG - Labor Langenthal, Switzerland.
⁴⁸ Stadtspital Triemli Zürich Zurich, Switzerland.
⁴⁹ Unilabs Breganzona, Switzerland.
⁵⁰ Unilabs Coppet - Core Lab Ouest Coppet, Switzerland.
⁵¹ Unilabs Dübendorf - Core Lab Ost Dübendorf, Switzerland.
⁵² Universität Bern Klinische Mikrobiologie Bern, Switzerland.
⁵³ Universität Spital Basel Basel, Switzerland.
⁵⁴ Universität Spital Zürich Zürich, Switzerland.
⁵⁵ Viollier AG Allschwill, Switzerland.
⁵⁶ Zentrum für Labormedizin St-Gallen, Switzerland.

PMID: 39447746
DOI: 10.1016/j.cmi.2024.10.012

No abstract available

PubMed Disclaimer

Cited by

In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.
Boattini M, Gaibani P, Comini S, Costa C, Cavallo R, Broccolo F, Bianco G. Boattini M, et al. Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40064744 Free PMC article. Review.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates

Collaborators

Affiliations

Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates

Authors

Collaborators

Affiliations

Similar articles

Cited by

Publication types

LinkOut - more resources

Full Text Sources